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patients having dilated and GHLV with signiﬁcant left ventricu-
lar dysfunction without documented CAD before. EF% was com-
puted by Simpson's method. Epidemiological data and details of
risk factors were studied. CAG was done in all patients. Both
femoral and radial access taken. Treatment plan was modiﬁed
after CAG and viability study results depending upon the
CAD status. Follow up results at the end of four month were
analyzed.
Results: Out of 30 patients with dilated and GHLV with severe left
ventricular dysfunction, majority of patient (13) belong to age
group 40–49 years (45%) 21 patients had normal CAG (60%) and
5 patients had signiﬁcant CAD (20%). A total of 3 patients under-
went CABG and 1 patient had undergone angioplasty. Only
2 patients developed mild renal dysfunction and improved on
follow up.
Conclusions: CAD was seen in 20% of patients with dilated and
GHLV. CAG is safe even up to LVEF of as low as 20%. The triad of low
EF, signiﬁcant CAD and viable myocardium provides favorable
prognosis. Mild CAD needs optimized medication.
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Angiotensin-converting enzyme (ACE) and beta blockers are the drugs
which decrease mortality and increase longevity in patients with
heart failure.
Aims and objects: The incidence of heart failure in India is increas-
ing and it affects relatively younger patients. Present study aims to
identify the limiting factors in giving optimal medical manage-
ment in patients with heart failure.
Subjects and methods: This prospective descriptive study was
done at Kerala Institute of Medical Sciences Trivandrum, over a
2 years period from 1st June 2012. Three hundred consecutive
patients with NYHA class 3 or 4 with various etiology of heart
failure were identiﬁed and then all treated patients were analyzed.
Results: Of the 300 patients, 69% (n – 208) were males and 31% (n –
92) were females. Below 70 years there was male predominance of
heart failure but after the age of 70 there was female predomi-
nance.
In our study 94.6% (n = 284) of patients received loop diuretics,
mainly frusemide 55.6% (n – 167) and torsemide 39% (n – 117).
Thiazide diuretics were used infrequently. Metalazonewas used in
8% (n – 24) of patients with loop diuretics when renal failure was
present. Potassium sparing diuretics, spiranolactone were used in
45.6% (n – 137) of patients and eplerenone in 9.3% (n – 28). Only 34%
(n – 104) of patients received ACE or ARB, of which 23.6% (n – 71)
were on ACE inhibitors). ARBs were used by 11% (n – 33) of patients
who were intolerant to ACE inhibitors, mainly due to dry cough.
ACE inhibitors could not be used due to hypotension in 34% (n –
103) of patients and renal failure in 31% (n – 93) of patients. Beta
blockers could be used only in 43% (n – 130) of patients because of
hypotension in 60% (n – 102), bronchial asthma in 20% (34), bra-
dycardia in 15% (25), and chronic obstructive pulmonary disease in
5% (n – 9) of patients.
Conclusion: The mainstay in the management in heart failure
today is ACE inhibitors and beta blockers. We found limitations
in using ACE inhibitors due to comorbidities like renal failure
and hypotension. Beta blockers could be used only in 43% of
patients. Even when the cardiac failure was long standing per-
sistence of contraindications limits the use of ACE/ARB and beta
blockers.
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Background: Patients of STEMI withMVD are at higher risk of heart
failure, cardiogenic shock and associated with 2 time's higher
mortality during hospitalization. The aim of the study was to
compare the outcome of culprit vessel only PCI and multivessel
PCI during the index procedure or staged in patients with STEMI
and MVD.
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